KR102396059B1 - 신규 화합물 및 이의 제조방법 - Google Patents
신규 화합물 및 이의 제조방법 Download PDFInfo
- Publication number
- KR102396059B1 KR102396059B1 KR1020197004436A KR20197004436A KR102396059B1 KR 102396059 B1 KR102396059 B1 KR 102396059B1 KR 1020197004436 A KR1020197004436 A KR 1020197004436A KR 20197004436 A KR20197004436 A KR 20197004436A KR 102396059 B1 KR102396059 B1 KR 102396059B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- alkyl group
- hydrogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 145
- 238000000034 method Methods 0.000 title claims abstract description 75
- -1 pyrimido[6,1-a]isoquinolin-4-one compound Chemical class 0.000 claims abstract description 36
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 238000006243 chemical reaction Methods 0.000 claims description 104
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 62
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 50
- 239000001257 hydrogen Substances 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 239000002904 solvent Substances 0.000 claims description 42
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 30
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical group [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 29
- 230000008569 process Effects 0.000 claims description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 239000007868 Raney catalyst Substances 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 7
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 150000007942 carboxylates Chemical class 0.000 claims description 5
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical group [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 150000004703 alkoxides Chemical class 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000011056 potassium acetate Nutrition 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 229910052744 lithium Inorganic materials 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000003880 polar aprotic solvent Substances 0.000 claims description 3
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 claims 1
- CSOBIBXVIYAXFM-BYNJWEBRSA-N ensifentrine Chemical compound c-12cc(OC)c(OC)cc2CCn(c(n2CCNC(N)=O)=O)c-1c\c2=N/c1c(C)cc(C)cc1C CSOBIBXVIYAXFM-BYNJWEBRSA-N 0.000 abstract description 20
- 150000002825 nitriles Chemical class 0.000 abstract description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 46
- 239000000047 product Substances 0.000 description 44
- 239000002585 base Substances 0.000 description 31
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 24
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- 239000007858 starting material Substances 0.000 description 20
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 18
- 238000005804 alkylation reaction Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 239000003054 catalyst Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 239000012535 impurity Substances 0.000 description 12
- 229910021529 ammonia Inorganic materials 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000029936 alkylation Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 235000011181 potassium carbonates Nutrition 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- CIVQDIGHVMGTPD-UHFFFAOYSA-N pyrimido[6,1-a]isoquinolin-4-one Chemical class C1=CC=C2C=CN3C(=O)N=CC=C3C2=C1 CIVQDIGHVMGTPD-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940113088 dimethylacetamide Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 231100000024 genotoxic Toxicity 0.000 description 3
- 230000001738 genotoxic effect Effects 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000003863 metallic catalyst Substances 0.000 description 3
- 125000002560 nitrile group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
- VODKOOOHHCAWFR-UHFFFAOYSA-N 2-iodoacetonitrile Chemical compound ICC#N VODKOOOHHCAWFR-UHFFFAOYSA-N 0.000 description 2
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052788 barium Chemical group 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical group [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- AYJRCSIUFZENHW-UHFFFAOYSA-L barium carbonate Chemical compound [Ba+2].[O-]C([O-])=O AYJRCSIUFZENHW-UHFFFAOYSA-L 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical group [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Chemical group 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000011777 magnesium Chemical group 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000005543 phthalimide group Chemical group 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052701 rubidium Inorganic materials 0.000 description 2
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical group [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 2
- 238000010512 small scale reaction Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical group [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- XXOOBFLVVVIHTO-UHFFFAOYSA-N 1,2,3,6-tetrahydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=CC=CC2=CCN3C(=O)NCCC3=C21 XXOOBFLVVVIHTO-UHFFFAOYSA-N 0.000 description 1
- PVKCAQKXTLCSBC-UHFFFAOYSA-N 1h-isoquinolin-4-one Chemical compound C1=CC=C2C(=O)C=NCC2=C1 PVKCAQKXTLCSBC-UHFFFAOYSA-N 0.000 description 1
- KYGVEPLGHJUKBR-UHFFFAOYSA-N 2-[9,10-dimethoxy-4-oxo-2-(2,4,6-trimethylphenyl)imino-6,7-dihydropyrimido[6,1-a]isoquinolin-3-yl]acetonitrile Chemical compound C1(=C(C(=CC(=C1)C)C)N=C1N(C(N2C(C3=CC(=C(C=C3CC2)OC)OC)=C1)=O)CC#N)C KYGVEPLGHJUKBR-UHFFFAOYSA-N 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OCAQSCOTLKDCIJ-UHFFFAOYSA-N C1CNC(N2C1=C1C=CC=CC1CC2)=O Chemical compound C1CNC(N2C1=C1C=CC=CC1CC2)=O OCAQSCOTLKDCIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910000990 Ni alloy Inorganic materials 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- UCVMQZHZWWEPRC-UHFFFAOYSA-L barium(2+);hydrogen carbonate Chemical compound [Ba+2].OC([O-])=O.OC([O-])=O UCVMQZHZWWEPRC-UHFFFAOYSA-L 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- ZMCUDHNSHCRDBT-UHFFFAOYSA-M caesium bicarbonate Chemical compound [Cs+].OC([O-])=O ZMCUDHNSHCRDBT-UHFFFAOYSA-M 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical group OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012351 deprotecting agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229940052303 ethers for general anesthesia Drugs 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- KEDRKJFXBSLXSI-UHFFFAOYSA-M hydron;rubidium(1+);carbonate Chemical compound [Rb+].OC([O-])=O KEDRKJFXBSLXSI-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-NJFSPNSNSA-N hydroxyformaldehyde Chemical compound O[14CH]=O BDAGIHXWWSANSR-NJFSPNSNSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000010667 large scale reaction Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- CSOBIBXVIYAXFM-UHFFFAOYSA-N rpl-554 Chemical compound C1=2C=C(OC)C(OC)=CC=2CCN(C(N2CCNC(N)=O)=O)C1=CC2=NC1=C(C)C=C(C)C=C1C CSOBIBXVIYAXFM-UHFFFAOYSA-N 0.000 description 1
- WPFGFHJALYCVMO-UHFFFAOYSA-L rubidium carbonate Chemical compound [Rb+].[Rb+].[O-]C([O-])=O WPFGFHJALYCVMO-UHFFFAOYSA-L 0.000 description 1
- 229910000026 rubidium carbonate Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229910000018 strontium carbonate Inorganic materials 0.000 description 1
- WJMMDJOFTZAHHS-UHFFFAOYSA-L strontium;carbonic acid;carbonate Chemical compound [Sr+2].OC([O-])=O.OC([O-])=O WJMMDJOFTZAHHS-UHFFFAOYSA-L 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
[화학식 A]
[화학식 A]
[화학식 I] [화학식 II]
[화학식 B]
[화학식 A]
[화학식 C]
[화학식 Ia]
[화학식 B] [화학식 III]
[화학식 IV]
[화학식 A]
[화학식 D]
Claims (22)
- 하기 화학식(A)의 화합물인 니트릴 화합물 또는 이의 염:
[화학식 A]
상기 화학식(A) 중,
·R1 및 R2는 동일하거나 상이하고, 각각은 독립적으로 C1-C6 알킬기 또는 C2-C7 아실기이거나, 또는 R1 및 R2는 함께 C1-C6 알킬렌기를 형성하고;
·R3 및 R4는 동일하거나 상이하고, 각각은 독립적으로 수소, 할로겐 또는 C1-C6 알킬기이고;
·R5 및 R6은 동일하거나 상이하고, 각각은 독립적으로 수소, 할로겐 또는 C1-C6 알킬기이고;
·X는 CHR7, O 또는 NR7이고, R7은 수소 또는 C1-C6 알킬기이고; 및
·Ar은 0 내지 4개의 치환기로 치환된 C6-C10 아릴기이고, 이들 치환기 각각은 독립적으로 할로겐 또는 C1-C6 알킬기이다.
- 제3항에 있어서,
·R1 및 R2은 메틸이고;
·R3 및 R4는 수소이고;
·R5 및 R6은 수소이고;
·X는 CH2이고; 및
·Ar은 2,4,6-트리메틸페닐인 것인, 니트릴 화합물의 제조방법.
- 제3항에 있어서,
Y는 Cl, Br, I, -OC(O)RY, -OS(O)2RY 및 - S(O)2RY인 이탈기이고, 여기서 RY는 수소, C1-C6 알킬기, C1-C6 알콕시기 또는 C6-C10 아릴기이고, 상기 알킬기, 알콕시기 또는 아릴기는 니트로 및 할라이드로부터 선택되는 1 내지 6개의 기로 치환되거나 치환되지 않을 수 있고, 또는 Y는 Br, I, OMs, OTs, ONs, OAc 또는 OTf인 이탈기이고, 또는 Y는 Br인 이탈기인 것인, 니트릴 화합물의 제조방법.
- 제3항에 있어서,
상기 화학식(II)의 화합물의 양은 화학식(I)의 화합물의 0.5 내지 10.0 당량(equivalent)이고, 또는 상기 화학식(II)의 화합물의 양은 화학식(I)의 화합물의 1.0 내지 2.5 당량인 것인, 니트릴 화합물의 제조방법.
- 제3항에 있어서,
상기 방법은 염기의 존재 하에서 화학식(I)의 화합물과 화학식(II)의 화합물을 반응시키는 단계를 포함하는 것인, 니트릴 화합물의 제조방법.
- 제7항에 있어서,
상기 염기는 카보네이트, 하이드로겐 카보네이트, 알콕사이드, 카복실레이트 또는 아민을 포함하고, 또는 상기 염기는 리튬 카보네이트, 소듐 카보네이트, 포타슘 카보네이트, 세슘 카보네이트, 리튬 아세테이트, 소듐 아세테이트 또는 포타슘 아세테이트이고, 또는 상기 염기는 리튬 카보네이트 또는 소듐 아세테이트인 것인, 니트릴 화합물의 제조방법.
- 제7항에 있어서,
상기 염기의 양은 화학식(I)의 화합물의 1.0 내지 10.0 당량이고, 또는 상기 염기의 양은 화학식(I)의 화합물의 1.5 내지 3.0 당량인 것인, 니트릴 화합물의 제조방법.
- 제3항에 있어서,
상기 방법은 용매의 존재 하에서 화학식(I)의 화합물과 화학식(II)의 화합물을 반응시키는 단계를 포함하는 것인, 니트릴 화합물의 제조방법.
- 제3항에 있어서,
상기 방법은 적어도 5시간 동안 화학식(I)의 화합물과 화학식(II)의 화합물을 반응시키는 단계를 포함하는 것인, 니트릴 화합물의 제조방법.
- 제3항에 있어서,
상기 방법은 50 내지 100 ℃의 온도에서 화학식(I)의 화합물 및 화학식(II)의 화합물을 반응시키는 단계를 포함하는 것인, 니트릴 화합물의 제조방법.
- 하기 화학식(B)의 화합물의 제조방법으로서,
[화학식 B]
상기 방법은 하기 화학식(A)의 화합물을 환원시키는 단계를 포함하는 것인, 화학식(B)의 화합물의 제조방법:
[화학식 A]
상기 화학식(A) 중,
·R1 및 R2는 동일하거나 상이하고, 각각은 독립적으로 C1-C6 알킬기 또는 C2-C7 아실기이거나, 또는 R1 및 R2는 함께 C1-C6 알킬렌기를 형성하고;
·R3 및 R4는 동일하거나 상이하고, 각각은 독립적으로 수소, 할로겐 또는 C1-C6 알킬기이고;
·R5 및 R6은 동일하거나 상이하고, 각각은 독립적으로 수소, 할로겐 또는 C1-C6 알킬기이고;
·X는 CHR7, O 또는 NR7이고, R7은 수소 또는 C1-C6 알킬기이고; 및
·Ar은 0 내지 4개의 치환기로 치환된 C6-C10 아릴기이고, 이들 치환기 각각은 독립적으로 할로겐 또는 C1-C6 알킬기이다.
- 제13항에 있어서,
상기 화학식(A)의 화합물을 환원시키는 단계는 니켈, 레이니 니켈(Raney nickel), 팔라듐, 팔라듐 블랙, 팔라듐 하이드록사이드, 플래티넘 및 플래티넘 다이옥사이드, 또는 레이니 니켈의 존재 하에서 화학식(A)의 화합물을 수소화하는 단계를 포함하는 것인, 화학식(B)의 화합물의 제조방법.
- 제13항에 있어서,
상기 방법은 제3항 내지 제12항 중 어느 한 항에 정의된 방법에 의해 화학식(A)의 화합물을 제조하는 단계를 더 포함하는 것인, 화학식(B)의 화합물의 제조방법.
- 하기 화학식(C)의 화합물의 제조방법으로서,
[화학식 C]
상기 화학식(C) 중, R1, R2, R3, R4, R5, R6, X 및 Ar은 제1항 내지 제4항 중 어느 한 항에 정의된 바와 같고, Q는 O, NR8 또는 CR8이고, 여기서 R8는 수소 또는 C1-C6 알킬기이고,
상기 제조방법은,
(i) 제3항 내지 제12항 중 어느 한 항에 정의된 바와 같은 화학식(A)의 화합물의 제조방법; 및
(ii) 하기 화학식(A)의 화합물의 환원에 의한 하기 화학식(B)의 화합물의 제조방법; 중 하나 이상을 포함하는 것이고,
[화학식 A]
[화학식 B]
,
이 때 화학식 (A) 및 화학식 (B)에서,
·R1 및 R2는 동일하거나 상이하고, 각각은 독립적으로 C1-C6 알킬기 또는 C2-C7 아실기이거나, 또는 R1 및 R2는 함께 C1-C6 알킬렌기를 형성하고;
·R3 및 R4는 동일하거나 상이하고, 각각은 독립적으로 수소, 할로겐 또는 C1-C6 알킬기이고;
·R5 및 R6은 동일하거나 상이하고, 각각은 독립적으로 수소, 할로겐 또는 C1-C6 알킬기이고;
·X는 CHR7, O 또는 NR7이고, R7은 수소 또는 C1-C6 알킬기이고; 및
·Ar은 0 내지 4개의 치환기로 치환된 C6-C10 아릴기이고, 이들 치환기 각각은 독립적으로 할로겐 또는 C1-C6 알킬기인 것인, 화학식(C)의 화합물의 제조방법.
- 제16항에 있어서,
상기 방법은,
(a) 상기 화학식(A)의 화합물을 환원시킴으로써 상기 화학식(B)의 화합물을 제조하는 단계; 및
(b) 상기 화학식(B)의 화합물을 더 반응시켜, 화학식(C)의 화합물을 수득하는 단계;를 포함하는 것인, 화학식(C)의 화합물의 제조방법.
- 제17항에 있어서,
상기 단계(b)는 요소화 반응(ureation reaction)인 것인, 화학식(C)의 화합물의 제조방법.
- 제16항에 있어서,
·R1 및 R2은 메틸이고;
·R3 및 R4는 수소이고;
·R5 및 R6은 수소이고;
·X는 CH2이고;
·Ar은 2,4,6-트리메틸페닐이고; 및
·Q는 0인 것인, 화학식(C)의 화합물의 제조방법.
- 제10항에 있어서,
상기 용매는 극성 비양자성 용매를 포함하고, 또는 상기 용매는 아세토니트릴, 테트라하이드로푸란 또는 디옥산을 포함하는 것인, 니트릴 화합물의 제조방법.
- 제12항에 있어서,
상기 방법은 환류 하에 용매의 존재 하에서 화학식(I)의 화합물 및 화학식(II)의 화합물을 반응시키는 단계를 포함하는 것인, 니트릴 화합물의 제조방법.
- 제18항에 있어서,
상기 요소화 반응은 화학식(B)의 화합물과 화합물 O=C=N-Z+가 반응함으로써 수행되고, 식 중 Z+는 금속 양이온이고, 또는 Z+는 소듐 또는 포타슘인 것인, 화학식(C)의 화합물의 제조방법.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1613054.4A GB201613054D0 (en) | 2016-07-28 | 2016-07-28 | New compound and process |
| GB1613054.4 | 2016-07-28 | ||
| PCT/GB2017/052190 WO2018020249A1 (en) | 2016-07-28 | 2017-07-27 | New compound and process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190034231A KR20190034231A (ko) | 2019-04-01 |
| KR102396059B1 true KR102396059B1 (ko) | 2022-05-10 |
Family
ID=56936838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197004436A Active KR102396059B1 (ko) | 2016-07-28 | 2017-07-27 | 신규 화합물 및 이의 제조방법 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10710998B2 (ko) |
| EP (1) | EP3490988B1 (ko) |
| JP (1) | JP6985367B2 (ko) |
| KR (1) | KR102396059B1 (ko) |
| CN (1) | CN109641891B (ko) |
| CY (1) | CY1122138T1 (ko) |
| DK (1) | DK3490988T3 (ko) |
| ES (1) | ES2751948T3 (ko) |
| GB (1) | GB201613054D0 (ko) |
| HR (1) | HRP20192109T1 (ko) |
| HU (1) | HUE046509T2 (ko) |
| LT (1) | LT3490988T (ko) |
| PL (1) | PL3490988T3 (ko) |
| PT (1) | PT3490988T (ko) |
| RS (1) | RS59566B1 (ko) |
| SI (1) | SI3490988T1 (ko) |
| SM (1) | SMT201900582T1 (ko) |
| TW (1) | TWI739871B (ko) |
| WO (1) | WO2018020249A1 (ko) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3231444T1 (sl) | 2014-05-12 | 2020-04-30 | Verona Pharma Plc | Novo zdravljenje |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| EP4090654B1 (en) * | 2020-01-17 | 2025-07-09 | Lupin Limited | Methods, processes and intermediates for preparing chroman compounds |
| JP2024517583A (ja) | 2021-04-29 | 2024-04-23 | ▲蘇▼州盛迪▲亞▼生物医▲薬▼有限公司 | イソキノリノン系化合物及びその用途 |
| WO2023109802A1 (zh) * | 2021-12-14 | 2023-06-22 | 海思科医药集团股份有限公司 | 三环稠杂环类pde3/4双重抑制及其用途 |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| WO2025003643A1 (en) | 2023-06-26 | 2025-01-02 | Verona Pharma Plc | Particulate composition comprising ensifetrine |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Plc公司 | 顆粒組成物 |
| US20250073240A1 (en) | 2023-09-06 | 2025-03-06 | Verona Pharma Plc | New treatment |
| US20250249008A1 (en) | 2024-02-07 | 2025-08-07 | Verona Pharma Plc | Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease |
| WO2025168706A1 (en) | 2024-02-07 | 2025-08-14 | Verona Pharma Plc | Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary disease |
| WO2025176871A1 (en) | 2024-02-23 | 2025-08-28 | Inke, S.A. | Process for preparing pyrimido[6,1-a]isoquinoline-4-ones |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000058308A1 (en) | 1999-03-31 | 2000-10-05 | Vernalis Limited | DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ185900A (en) | 1976-12-10 | 1981-04-24 | Hoechst Ag | Pyrimido (6,1-a) isoquinolin-4-ones medicaments intermediate isoquinolines |
| FI64370C (fi) | 1977-05-05 | 1983-11-10 | Hoechst Ag | Foerfarande foer framstaellning av terapeutiskt anvaendbara pyimido-(6,1-a)isokinolin-2-imino-4-onderivat |
| DE2847693A1 (de) | 1978-11-03 | 1980-05-22 | Hoechst Ag | Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen |
| DE3135831A1 (de) | 1981-09-10 | 1983-04-28 | Hoechst Ag, 6230 Frankfurt | 9,10-substituierte 2-mesitylimino-3-alkyl-3,4,6,7-tetrahydro-2h-pyrimido(6,1-a)isochinolin-4-one, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| CA1237429A (en) | 1983-05-05 | 1988-05-31 | Frank Kienzle | Pyrimidone derivatives |
| PH12013500261A1 (en) | 2010-08-09 | 2013-03-04 | Verona Pharma Plc | Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound |
| PT2968313T (pt) | 2013-03-15 | 2018-02-21 | Verona Pharma Plc | Combinação de fármacos |
| SI3231444T1 (sl) | 2014-05-12 | 2020-04-30 | Verona Pharma Plc | Novo zdravljenje |
| DK3494962T3 (da) | 2014-09-15 | 2021-06-21 | Verona Pharma Plc | Flydende inhalationsformulering omfattende RPL554 |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2016
- 2016-07-28 GB GBGB1613054.4A patent/GB201613054D0/en not_active Ceased
-
2017
- 2017-07-27 KR KR1020197004436A patent/KR102396059B1/ko active Active
- 2017-07-27 ES ES17748880T patent/ES2751948T3/es active Active
- 2017-07-27 US US16/309,435 patent/US10710998B2/en active Active
- 2017-07-27 LT LTEP17748880.6T patent/LT3490988T/lt unknown
- 2017-07-27 TW TW106125312A patent/TWI739871B/zh active
- 2017-07-27 RS RS20191474A patent/RS59566B1/sr unknown
- 2017-07-27 JP JP2019503748A patent/JP6985367B2/ja active Active
- 2017-07-27 HU HUE17748880A patent/HUE046509T2/hu unknown
- 2017-07-27 DK DK17748880T patent/DK3490988T3/da active
- 2017-07-27 WO PCT/GB2017/052190 patent/WO2018020249A1/en not_active Ceased
- 2017-07-27 PT PT177488806T patent/PT3490988T/pt unknown
- 2017-07-27 EP EP17748880.6A patent/EP3490988B1/en active Active
- 2017-07-27 SI SI201730098T patent/SI3490988T1/sl unknown
- 2017-07-27 PL PL17748880T patent/PL3490988T3/pl unknown
- 2017-07-27 SM SM20190582T patent/SMT201900582T1/it unknown
- 2017-07-27 CN CN201780046788.1A patent/CN109641891B/zh active Active
- 2017-07-27 HR HRP20192109TT patent/HRP20192109T1/hr unknown
-
2019
- 2019-10-04 CY CY20191101046T patent/CY1122138T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000058308A1 (en) | 1999-03-31 | 2000-10-05 | Vernalis Limited | DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE |
Non-Patent Citations (1)
| Title |
|---|
| Journal of Medical Chemistry, Vol. 27(11), pp. 1470-1480(1984) |
Also Published As
| Publication number | Publication date |
|---|---|
| RS59566B1 (sr) | 2019-12-31 |
| TWI739871B (zh) | 2021-09-21 |
| EP3490988A1 (en) | 2019-06-05 |
| TW201806951A (zh) | 2018-03-01 |
| JP6985367B2 (ja) | 2021-12-22 |
| CN109641891B (zh) | 2021-05-04 |
| HUE046509T2 (hu) | 2020-03-30 |
| SI3490988T1 (sl) | 2019-11-29 |
| EP3490988B1 (en) | 2019-08-28 |
| ES2751948T3 (es) | 2020-04-02 |
| KR20190034231A (ko) | 2019-04-01 |
| GB201613054D0 (en) | 2016-09-14 |
| US20190330206A1 (en) | 2019-10-31 |
| PL3490988T3 (pl) | 2020-02-28 |
| SMT201900582T1 (it) | 2019-11-13 |
| LT3490988T (lt) | 2019-10-10 |
| PT3490988T (pt) | 2019-10-28 |
| CY1122138T1 (el) | 2020-11-25 |
| WO2018020249A1 (en) | 2018-02-01 |
| HRP20192109T1 (hr) | 2020-02-21 |
| DK3490988T3 (da) | 2019-10-28 |
| CN109641891A (zh) | 2019-04-16 |
| JP2019527228A (ja) | 2019-09-26 |
| US10710998B2 (en) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102396059B1 (ko) | 신규 화합물 및 이의 제조방법 | |
| CN116987112B (zh) | 制备氨基嘧啶衍生物的改善方法 | |
| TW201713652A (zh) | 雜環化合物的合成 | |
| CN113767094B (zh) | 3-甲基-1,2,4-噻二唑-5-碳酰肼及其甲基-d3氘代形式的合成 | |
| EP3303304B1 (en) | Methods of making protein deacetylase inhibitors | |
| TW201625634A (zh) | 科帕利普(copanlisib)及其二鹽酸鹽之合成 | |
| EA038078B1 (ru) | Промежуточные соединения, используемые для синтеза селективного ингибитора протеинкиназы, и способы их получения | |
| CN112824381B (zh) | 一种哌啶胺的制备方法 | |
| WO2013059572A1 (en) | Process for the preparation of etravirine and intermediates in the synthesis thereof | |
| HK40002783A (en) | New compound and process | |
| HK40002783B (en) | New compound and process | |
| US6340773B1 (en) | Preparation of halogenated primary amines | |
| CN113816955B (zh) | 一种ret激酶抑制剂中间体及其制备方法 | |
| US11780824B2 (en) | Process for preparing osimertinib or a salt thereof | |
| RU2804686C2 (ru) | СИНТЕЗ 3-МЕТИЛ-1,2,4-ТИАДИАЗОЛ-5-КАРБОГИДРАЗИДА ИЛИ ЕГО МЕТИЛ-d3 ДЕЙТЕРИРОВАННОЙ ФОРМЫ | |
| CN119638647A (zh) | 制备氧杂环丁烷-2-基甲胺或其盐的方法 | |
| EP4375282A1 (en) | Preparation method for hepatitis b virus nucleocapsid inhibitor | |
| JP2024080578A (ja) | ミラベグロン及びその製造中間体の製造方法 | |
| CN120424067A (zh) | 并环化合物的制备方法及其中间体 | |
| WO2024251227A1 (zh) | 一种甲酰胺类化合物的制备方法 | |
| CN105849115A (zh) | 制药方法和中间体 | |
| HK1231871A1 (en) | A process for the preparation of compound and synthetic intermediates thereof | |
| HK1241883B (zh) | Copanlisib及其二盐酸盐的合成 | |
| HK1205105A1 (zh) | 制备化合物的方法及其合成中间体 | |
| JP2009114123A (ja) | 2−アシル−1−アミノピロール化合物の新規製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190214 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200716 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211216 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220420 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220504 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220506 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |